FDA Revisits Old Issues For Novartis' COPD Drug Indacaterol At Panel Review

The Pulmonary-Allergy Drugs Advisory Committee is being asked whether safety and efficacy have been established for two doses of the chronic obstructive pulmonary disease treatment Arcapta, the same problem that caused an earlier "complete response" letter.